Scandion Oncology A/S meets with Big Pharma at ”Focus on Cancer Collaboration” at Medicon Village, Lund, Sweden April 24th

CMO Nils Brünner will present the background and status of Scandion Oncology A/S, highlighting that the main drug SCO-101 is ready for Phase II studies.

Co-funded by the Horizon 2020 programme of the European Union
Co-funded by the COSME programme of the European Union